The medical research data coming out of Q1 2026 indicates a hard pivot in clinical strategy. We are moving past the era of the blunt-force "blockbuster" drug. Instead, the focus across major symposiums this year is on "precision intensification"—using real-time biomarkers to decide exactly how long, and how aggressively, we need to treat a patient before safely de-escalating. For frontline clinicians, the most impactful research this quarter isn't just about novel molecules.
